Lundbeck highlights cognitive improvements in migraine according to study
The Danish pharmaceutical company Lundbeck presents new real-world data from the INFUSE study at AAN 2026.
ANNONS
The results show that patients with migraine report improved cognitive symptoms, such as brain fog and difficulty concentrating, after treatment with eptinezumab.
More than 50 percent reported improvement in several symptoms after six months, with effects already after one week. The study includes patients who had previously not responded to other CGRP treatment.
"These real-world, patient-reported INFUSE data provide deeper insight into managing the combined burden of migraine – including very common cognitive symptoms – to better support optimal treatment decisions," says Damian Fiore, Head of Medical Affairs Neurology at Lundbeck in the US.
"We look forward to sharing new data that can help redefine expectations for preventive migraine treatment and strengthen our commitment to raising the standard of migraine care," he continues.
